There are 702 resources available
63P - FOLFOXIRI/bevacizumab (bev) versus doublets/bev as initial therapy of unresectable liver-only (LL), right-sided and/or RAS or BRAF mutated (mut) metastatic colorectal cancer (mCRC): An individual patient data-based pooled analysis of randomized trials
Presenter: Federica Marmorino
Session: Poster Display session
64P - Long-term response to regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A systematic literature review (SLR)
Presenter: Marc Peeters
Session: Poster Display session
65P - Costs and resource utilization in the curative and palliative treatment phases of metastatic colorectal cancer: Patient-level data analysis of the Finnish RAXO study
Presenter: Pia Osterlund
Session: Poster Display session
66P - Targeted treatment (TT) after immune checkpoint inhibitors (ICIs) in BRAF V600E mutated (BRAFm) and deficient mismatch repair or microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC)
Presenter: Margherita Ambrosini
Session: Poster Display session
67P - Relevance of local treatment with curative intent (LT) against metastatic colorectal cancer (mCRC): Findings of a retrospective cohort study at the Comprehensive Cancer Center Munich (CCC MunichLMU)
Presenter: Jo-Ann Eisenburger
Session: Poster Display session
68P - Post-treatment ctDNA analysis reveals patterns of HER2 therapy resistance in advanced HER2-amplified colorectal cancer
Presenter: Celine Hoyek
Session: Poster Display session
69P - Circulating tumor DNA (ctDNA) dynamics in response to hepatic artery infusion pump therapy
Presenter: Michelle Chung
Session: Poster Display session
70P - Intra-arterial hepatic chemotherapy in metastatic colorectal cancer: A successful method for oxaliplatin rechallenge?
Presenter: Elsa El Rawadi
Session: Poster Display session
71P - Real-world treatment patterns in patients with metastatic colorectal cancer in the Netherlands
Presenter: Marloes Elferink, Jeanine Roodhart
Session: Poster Display session
72P - The RAS status change in mCRC after progression on the first-line therapy using the Idylla RT- PCR platform
Presenter: Hampig Raphael Kourie
Session: Poster Display session